![ODAC: Thumbs up for Eli Lilly's Cyramza, thumbs down for STEBA's Tookad](https://cdn.cancerletter.com/media/2020/02/25200302/ODAC_4x3.jpg)
![ODAC: Thumbs up for Eli Lilly's Cyramza, thumbs down for STEBA's Tookad](https://cdn.cancerletter.com/media/2020/02/25200302/ODAC_4x3.jpg)
Cover Story
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
By Alexandria Carolan
In Brief
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- What are you reading in 2024?
- FDA’s Brian Booth: “We need to reconsider our approach to dose selection”
- Wafik El-Deiry carted a bunch of books around the Mediterranean
Here are his reviews - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Before the Olympics were smoke-free, tobacco brand deals ran rampant